Access Statistics for Margaret K. Kyle

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 0 10 13
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 3 8 27
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 0 0 0 8 22
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 0 16 0 1 9 38
Assessing the population health impact of market interventions to improve access to antiretroviral treatment 0 0 0 0 0 0 4 12
COVID-19 and clinical trials 0 0 0 0 0 0 2 6
Competition Law, Intellectual Property, and the Pharmaceutical Sector 0 0 0 0 0 1 7 40
Competition and the Efficiency of Markets for Technology 0 0 0 94 1 2 19 154
Competition and the Efficiency of Markets for Technology 0 0 0 0 0 1 8 13
Competition and the Efficiency of Markets for Technology 0 0 0 0 0 0 5 8
Competition and the Efficiency of Markets for Technology 0 0 0 70 0 1 14 143
Competition law, intellectual property, and the pharmaceutical sector 0 0 0 0 0 2 8 48
Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending? 0 0 0 189 1 1 14 833
Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? 0 0 0 138 0 0 6 538
Do Patents Work? Evidence from Pharmaceutical Innovation 0 0 0 0 0 0 3 19
Economic Issues in Assessing Potential and Nascent Competition 0 0 0 0 0 0 4 16
Estimating the Benefits of Cancer Treatments 0 0 0 0 0 1 4 13
Estimating the Benefits of Innovation 0 0 0 0 0 0 4 48
Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration 0 0 0 0 0 2 7 44
Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act 0 0 0 4 0 1 4 53
Government Free-riding in Research Funding 0 0 0 0 0 0 2 10
Hot tub time machine? What role for Towercast in EU merger control 0 0 0 0 0 6 12 17
Incentives for pharmaceutical innovation: What’s working, what’s lacking 0 0 0 1 0 0 12 20
Inefficiencies in technology transfer: theory and empirics 0 0 0 59 0 1 8 335
Inefficiencies in technology transfer: theory and empirics 0 0 0 0 0 1 5 7
Inefficiencies in technology transfer: theory and empirics 0 0 0 13 0 2 9 106
Inefficiencies in the sale of ideas: theory and empirics 0 0 0 106 0 1 10 129
Inefficiencies in the sale of ideas: theory and empirics 0 0 0 0 0 1 10 11
Innovation pharmaceutique: comment combler le retard français ? 0 0 0 1 0 1 4 19
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS 0 0 0 0 1 2 12 19
Intellectual Property Rights and Access to Innovation: Evidence from TRIPS 0 0 0 61 0 4 36 238
Intellectual property rights and access to innovation: evidence from TRIPS 0 0 0 0 0 1 13 52
Intersection of Intellectual Property and Competition Policy in Recent Cases 0 0 0 0 0 0 7 14
Investments in Pharmaceuticals Before and After TRIPS 0 0 0 41 0 1 16 173
Investments in Pharmaceuticals Before and After TRIPS 0 0 0 88 0 5 23 285
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 0 0 0 6 60
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 0 0 0 4 20
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 45 0 0 15 74
Korean pharmaceutical industry policy: lessons for Korea 0 0 0 0 0 0 2 8
Lessons for the United States from Pharmaceutical Regulation Abroad 0 0 0 0 0 2 4 4
Productivity and competitiveness in the euro area: A view from France 0 0 0 0 0 1 9 81
Productivity and competitiveness in the euro area: A view from France 0 0 0 0 1 3 10 21
Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research 0 0 0 125 0 0 19 386
Strategic Interaction Among Governments in the Provision of a Global Public Good 0 0 0 30 1 2 10 78
Strategic Responses to Parallel Trade 0 1 1 132 0 3 13 406
Strategic interaction among governments in the provision of a global public good 0 0 0 0 0 0 7 17
Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates 0 0 0 0 0 0 8 137
TRIPS, Pharmaceutical Patents, and Generic Competition in India 0 0 0 0 0 1 5 5
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 0 0 0 18 19
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 0 1 1 4 8
The Effects of Pharmaceutical Innovation on Cancer Mortality 0 0 1 11 0 0 14 60
The Effects of Pharmaceutical Innovation on Cancer Mortality Rates 1 2 6 104 2 4 24 225
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 0 0 0 0 5 64
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 0 23 0 3 15 104
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect* 0 0 0 0 0 0 12 18
The Single Market in Pharmaceuticals 0 0 0 0 0 0 5 18
The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation 0 0 0 3 0 0 6 16
Total Working Papers 1 3 8 1,354 8 62 542 5,352
1 registered items for which data could not be found

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets 0 0 2 32 2 4 21 111
Competition and the Efficiency of Markets for Technology 0 0 0 21 1 2 25 111
Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales 0 0 2 31 2 2 13 150
Does locale affect R&D productivity? the case of pharmaceuticals 0 0 0 26 0 0 2 99
Generic competition and market exclusivity periods in pharmaceuticals 0 0 9 190 4 7 40 525
Incentives for pharmaceutical innovation: What’s working, what’s lacking 0 0 0 13 0 4 19 60
Intellectual Property Protection and the Geography of Trade 0 0 1 41 0 1 10 221
Investments in Pharmaceuticals Before and After TRIPS 0 0 4 191 1 5 32 604
Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs 0 0 0 12 0 0 11 146
Lessons for the United States from Pharmaceutical Regulation Abroad 0 0 4 6 1 1 41 48
Objective and self‐report work performance measures: a comparative analysis 0 0 0 1 0 2 8 11
Pharmaceutical Price Controls and Entry Strategies 0 2 11 544 6 11 59 1,269
Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research 0 1 1 16 0 1 17 118
Strategic Responses to Parallel Trade 0 0 0 96 0 0 11 364
Strategic interaction among governments in the provision of a global public good 1 1 1 15 3 3 18 102
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 12 0 1 23 81
The More We Die, The More We Sell? A Simple Test of the Home-Market Effect 0 0 2 25 0 0 16 231
The Single Market in Pharmaceuticals 0 0 0 21 0 1 8 96
The role of firm characteristics in pharmaceutical product launches 0 0 0 21 0 0 2 84
Total Journal Articles 1 4 37 1,314 20 45 376 4,431

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
COVID-19 and clinical trials 0 0 0 0 1 1 1 1
Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending? 0 0 0 45 0 2 17 188
Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions 0 0 3 79 0 3 17 242
Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity 1 2 8 121 2 7 33 435
Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research 0 0 0 0 0 0 4 95
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals 0 0 0 19 0 2 27 88
The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches 0 0 0 105 0 1 12 337
Total Chapters 1 2 11 369 3 16 111 1,386

Software Item File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
MATLAB/C code for GIG and BNLG common value auction specifications 0 0 0 1,673 2 2 17 5,729
Total Software Items 0 0 0 1,673 2 2 17 5,729

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-08-07